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Abstract We used an antithrombin autoantibody (IgG D), the 
epitope of which encompasses ABE1 and amino acids located 
within variable region 1, to study thrombin interactions with R358 
al-AT and protein C. IgG D inhibited the thrombin interaction 
with R358 aI-AT, while hirugen had no effect, indicating that the 
interaction of R358 al-AT with thrombin may involve the VR1 
subsite. We also obtained evidence that VR1 may be involved in 
the activation of protein C by thrombin in the absence of throm- 
bomodufin. Moreover, lgG D attenuated the inhibitory effect of 
calcium ions during protein C activation by thrombin, probably 
by masking E 39 within the VRI site. 
Key words: Thrombin; Variable region; Autoantibody; 
Protein C; R358 ~l-antitrypsin 
1. Introduction 
An antihuman thrombin autoantibody was discovered in a 
patient with recurrent unexplained thrombosis [1]. The purified 
antibody (IgG D) was found to inhibit thrombin binding to 
thrombomodulin, fibrinogen recognition, inhibition of throm- 
bin by heparin cofactor II, and platelet and endothelial cell 
thrombin receptor activation [1,2]. These properties suggested 
that IgG D bound to an exosite known as anion binding exosite 
1 (ABE1). Experiments with recombinant thrombin identified 
two critical domains for thrombin recognition by IgG D. One 
involves H71, R73 and R75 chymotrypsin umbering system), 
which are part of ABE1. A second set of amino acids, P37, Q38 
and E39, are also part of the IgG D epitope [3]. This domain 
belongs to thrombin variable region 1 (VRI), the entire se- 
quence of which (F34 to L40) is involved in substrate specificity 
and inhibitor (serpin) recognition. E39 (together with R35) 
forms part of a hydrophilic dipole known as the $3' subsite, 
which is a putative specificity site C-terminal to the cleavage 
point (for a review see [4,5]). 
E39 also has a negative influence on the cleavage of protein 
C by thrombin in the absence of thrombomodulin [6]. Recent 
data [7] show that E39 and E192 are involved in ionic interac- 
tions between thrombin and protein C. In three-dimensional 
models, E192, together with some other negatively charged 
amino acids, is located close to the thrombin active site, Hy- 
drophilic residues uch as E39 and E192 may be responsible for 
specific electrostatic interactions, that depend on the calcium 
ion concentration [8]. Moreover, E39 might be involved in 
repulsive charges between thrombin and the P3' Asp residue of 
protein C, which could be responsible for inhibiting protein C 
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activation by thrombin alone. This effect is reinforced by cal- 
cium ions and attenuated by the binding of thrombin to throm- 
bomodulin [9-13]. 
We took advantage of the specificity of IgG D to determine 
the role of VR1 in the interaction of thrombin with a mutated 
~l-antitrypsin (M358 R) and with protein C. 
2. Materials and methods 
2.1. Reagents and proteins 
The thrombin-selective synthetic substrates S 78, S 101, S 109, S 147, 
S 149, S 150 and S 157 were kindly provided by F. Nicham (Serbio 
Laboratories, Gennevilliers, France). The other synthetic substrates 
(S 2366 for activated protein C and S 2238 for thrombin) were from 
Chromogenix (Mrlndal, Sweden). Chelating resin imminodiacetic a id 
was from Sigma (St. Louis, MO). The C-terminal hirudin (hirugen, 
NDGDFEEIPEEYLQ) was synthesized and purified by Dr. F. Troalen 
(Institut Gustave-Roussy, Villejuif, France). It was tested for its antico- 
agulant properties and found to increase the plasma thrombin time at 
concentrations above 1/.tM. 
Human thrombin and protein C were from Diagnostica Stago 
(Asnirres, France). Antithrombin was purified as described elsewhere 
[14]. Human R358 ~I-AT was isolated from the plasma ofa 15-year-old 
boy [15]. 
Ig G from the patient (IgG D) and from normal control subjects were 
obtained through a three-step rocedure involving ammonium sulfate 
precipitation, anion-exchange chromatography (Q-Sepharose, Phar- 
macia, Uppsala, Sweden) and protein G-Sepharose affinity as described 
in [2]. 
2.2. Effects of lgG D on the interaction between thrombin and 
R358 ~l-antitrypsin (R358 ~I-AT) 
We tested the effects of IgG D on the pseudo first-order rate constant 
for thrombin inhibition by R358 ~I-AT and by antithrombin. Throm- 
bin (18 nM final) was prewarmed at 37°C and added with control IgGs 
and IgG D (0 to 1 ,uM final) in Tris/0.1 M NaC1 buffer (pH 7.4) 
containing 0.5% (v/w) polyethylene glycol 6000. R358 ~I-AT was im- 
mediately added (200 to 400 nM) for exactly 1 min at 37°C. Residual 
thrombin protease activity was quantified from the initial velocity (A) 
of 2 mM S 2238 substrate hydrolysis, monitored at 405 nm in an 
Eppendorf spectrophotometer (Roucaire, Vrlizy, France). The ob- 
served pseudo first-order constant was calculated using the formula 
k = In Ao - lnA/t, where A 0 was measured in the presence of control 
IgGs. 
The same experiment was performed using hirugen (0 to 20 ,uM) 
instead of IgG D as a competitor for the binding of R358 cO-AT to 
thrombin. 
The interaction between human antithrombin (250 nM) and throm- 
bin (25 nM) was tested as described elsewhere [1] in the presence of 
control IgGs and IgG D (0 to 1/.tM). Residual thrombin activity was 
quantified as described for R358 al-AT. 
2.3. Effects of lgG D on protein C activation by thrombin 
Protein C (0.56/.tM) was added with 1/~M control IgGs or IgG D 
in 20 mM Tris/0.1 M NaC1 buffer, pH 7.4, containing 0.1% bovine 
serum albumin (w/v) and 0 to 700/IM CaCI2 at room temperature. The 
buffer was passed through a chelating resin column prior to the addi- 
tion of calcium, to remove any contaminating divalent ions. Human 
thrombin (25 nM) was then added at 37°C. Protein C activation rates 
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were determined by placing aliquots in a 96-well microplate after 2, 4 
and 8 min of incubation, according to Zhang and Castellino [16]. The 
reaction was stopped by adding 4 #M antithrombin and 0.14 IU/ml 
heparin to each well. The amount of activated protein C was deter- 
mined at 405 nm with 0.8 mM S 2366 substrate on a MR5000 micro- 
plate reader (Dynatech Laboratories, Saint Cloud, France). The graph 
of each protein C activation time (abcissa) versus the initial velocity of 
substrate hydrolysis is a straight line, the slope of which gives the 
activation rate of protein C (Vi, AA. min 2). 
2.4. Effect of lgG D on synthetic substrate hydrolysis by thrombin 
Thrombin (10 to 60 nM final) was incubated for 10 min at room 
temperature with control IgGs or IgG D (1 #M final), then each sub- 
strate was added (0.3 mM) and the initial velocity of substrate hydrol- 
ysis by thrombin was measured at 405 nm. 
3. Results 
3.1. Effects of lgG D on the interaction ofR358 otl-AT with 
human thrombin 
IgG D competed with R358 ~I-AT for binding to thrombin 
in experiments with three R358 czl-AT concentrations and in- 
creasing amounts of IgG D and this effect was not observed 
with control IgGs. IgG D produced a concentration-dependent 
inhibition of thrombin/R358 ~I-AT complex formation. The 
pseudo first-order ate constant was calculated and the inhibi- 
tion constant (Ki = 190 nM) was determined graphically (see 
Fig. 1). 
Hirugen (0 to 20 #M) failed to displace R358 ~I-AT from 
its binding site on thrombin, as shown in Fig. 2 fir three concen- 
trations of R358 ~I-AT. 
3.2. Interaction of lgG D with antithrombin for binding to 
thrombin 
As previously observed [1], thrombin binding to antithrom- 
bin was unaffected by IgG D. The observed pseudo first-order 
rate constants were 0.180, 0.235 and 0.240 min -1, respectively, 
in the absence of IgGs, in the presence of control IgGs and in 
the presence of IgG D (560 nM) (not shown). 
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Fig. 1. Effect of IgG D on thrombin inhibition by R358 c~l-antitrypsin. 
Thrombin (18 nM) was incubated with IgG D (0 to 0.6/IM) and R358 
~I-AT was added for exactly one min at 37°C. Residual thrombin 
activity was quantified at 405 nm by the initial velocity of S 2238 
substrate hydrolysis. The observed pseudo first-order constant was 
given by the formula k = In Ao - lnAlt, where A0 was measured in the 
presence of control IgGs. The inhibition constant K~ was graphically 
determined according to the method of Dixon. The concentrations of 
R358 ~I-AT were 200 nM (e), 300 nM (11), and 400 nM (,). 
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Fig. 2. Effect ofhirugen on thrombin inhibition by R358 czl-antitrypsin. 
Thrombin (10 nM) was incubated with various concentrations 
of R358 ~l-antitrypsin and 0 to 20/~M hirugen. Residual thrombin 
activity was quantified as described in Fig. 1. The concentrations of
R358 gl-AT were 80 nM (O), 160 nM (E), and 240 nM( . ) .  
In the presence of increasing heparin concentrations (10 -3 to 
10 -9 M), a bell-shaped curve was obtained by plotting the 
pseudo first-order ate constant against he heparin concentra- 
tion. Control IgGs and IgG D had no influence (not shown). 
3.3. Prote& C activation 
As shown in Fig. 3, the activation rate of protein C by 
thrombin was significantly reduced in the presence of 1/~M IgG 
D (Vi, 2.69 + 0.50 AA. min -2 versus 4.02 + 0.28 AA. rain -2 in the 
presence of control IgGs). 
As expected, calcium (0 to 700/.tM) induced a concentration- 
dependent inhibition of protein C activation by thrombin (Fig. 
4). The inhibition constant (Ki) for calcium ions was evaluated 
from the usual plots of the initial rate of protein C activation 
(1/V~, arbitrary units) against he concentration ofcalcium chlo- 
ride. As shown in Fig. 4 (inset), IgG D decreased the Ki 
(119 + 23 #M in the presence of control IgGs and 48 + 4 / IM  
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Fig. 3. Effect of IgG D on protein C activation by thrombin. Protein 
C (0.56 gM) was incubated with 25 nM human thrombin at 37°C. The 
reaction was stopped by adding 4 gM antithrombin and 0.14 IU/ml 
heparin. The histograms represent the V~ of the reaction, determined 
as described in Methods, in the presence of 1 /IM control IgGs 
(8 determinations) or 1 gM IgG D (7 determinations). 
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Fig. 4. Thrombin activation of protein C in the presence of IgG D and 
calcium ions. Protein C (0.56/tM) was incubated with 1/tM control 
IgGs (e) or lgG D (I) and 0 to 700 gM calcium chloride. Then 25 nM 
human thrombin was added and the activation rate of protein C (Vi) 
was determined after 2, 4 and 8 rain as described in section 2. The K~ 
of calcium ions for the reaction was determined as the negative intercept 
of the abcissa. The inset shows the results of four determinations (mean 
K~ + S.D.). 
in the presence of IgG D, P < 0.001), thus attenuating the 
inhibitory effect of calcium ions on protein C activation by 
thrombin alone. 
3.4. Synthetic substrates 
Thrombin (10 and 60 nM final) was incubated for 10 min at 
22°C with control IgGs or IgG D and quantified at 405 nm by 
the initial velocity of hydrolysis of seven synthetic substrates. 
As shown in Fig. 5, by comparison to control IgGs (mean of 
four determinations), IgG D did not inhibit substrate hydroly- 
sis but induced a slight increase in the V~ of the reaction. These 
results are consistent with an alteration of the thrombin confor- 
mation induced by IgG D binding. 
4. D iscuss ion  
An auto-antibody (IgG D) directed against human thrombin 
was isolated from a patient with recurrent arterial thrombosis. 
The IgG D recognized amino acids H71, R73 and R75 (located 
within ABE1) and inhibited all thrombin functions requiring 
the recognition of macromolecular substrates through ABE1 
[2]. We now report hat IgG D inhibits the thrombin interaction 
with a mutated serpin (R358 cO-AT) and also protein C activa- 
tion in the absence of thrombomodulin. Since ABE1 is not 
involved in these reactions [4], the inhibitory effect of IgG D 
may be explained by an allosteric hange subsequent to its 
binding to ABE1. The increased velocity of small-substrate 
hydrolysis indicates a thrombin more efficient catalytic site in 
the presence of IgG D and thus supports this hypothesis. In- 
deed, a similar effect was observed by Liu [17], who used a 
peptide from the thrombin receptor (residues 52-69) which 
bound to the ABE of thrombin and induced a conformational 
change in the active site. An alternative xplanation is that 
thrombin interaction with R358 czl-AT and with protein C in 
the absence of thrombomodulin i volves another site blocked 
by IgG D, the epitope of which comprises P37, Q38 and E39 
[3]. Indeed, the domain emcompassing this sequence (VR 1) was 
recently shown to be crucial for the interaction of the serpin 
PAI-1 with its target protease t-PA. The replacement of the 
thrombin VR1 subsite by the corresponding sequence of t-PA 
transforms PAI-1 into a potent hrombin inhibitor [18]. 
The role of VR 1 as a subsite for the interaction of thrombin 
with R358 ~I-AT could explain the strong inhibitory potency 
of the mutated czl-AT. The transformation of ~I-AT into a 
thrombin inhibitor on substitution of M by R is explained by 
the importance of the P1 residue in recognition by the target 
protease, which has now been observed with other serpins [19]. 
However, this does not account for why R358 czl-AT inhibits 
thrombin more rapidly than does the natural inhibitor an- 
tithrombin. A role of ABE1 can be ruled out, as hirugen, a 
peptide binding specifically to this domain, did not influence 
thrombin inhibition by R358 ~zl-AT. The candidate domain is 
thus thrombin VR1, while the corresponding domain in R358 
cO-AT remains to be determined. The PI '  to P5' sequences are 
SIPPE, SLNPN and MAPPE in ~I-AT, antithrombin and PAI- 
l, respectively. It is possible that the presence of the E in the 
P5' position (the C-terminal part of the reactive loop) is re- 
quired for the interaction with thrombin VR1. Indeed, IgG D 
does not affect hrombin inhibition by antithrombin (this study 
and [1]). 
The interaction of IgG D with protein C activation is com- 
plex. We have previously shown that the antibody inhibits the 
cleavage of protein C by thrombin in the presence of throm- 
bomodulin [2], probably through competition between IgG D 
and thrombomodulin for binding to thrombin ABE1. In the 
absence of thrombomodulin, IgG D also inhibits the activation 
of protein C by thrombin. This could result from the binding 
of the antibody to VR1, and suggests that this subsite plays a 
role in the recognition of the protein C cleavage site by throm- 
bin. The PI'P5' sequence of the cleavage site is LIDGK. The 
acidic residue in P3' position is involved in the inhibition of the 
reaction by calcium ions, possibly through repulsive charges 
between thrombin E39 and protein C D172 (P3'). That IgG D 
attenuated the inhibition of protein C by calcium ions confirms 
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Fig. 5. Thrombin synthetic substrate hydrolysis in the presence of IgG 
D. Substrates were used at a concentration f 0.3 mM. The % change 
is the ratio of the initial velocity of substrate hydrolysis by thrombin 
(10 and 60 nM) in the presence of 1 pM IgG D to the rate in the presence 
of control IgGs x 100. Data are means (+ S.D.) of four determinations. 
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this hypothesis and underlines the role of thrombin VR1 in 
protein C activation. 
In conclusion, the thrombin VR1 subsite appears to be in- 
volved in the thrombin/R358 ~I-AT and thrombin/protein C 
interactions. IgG D attenuated the inhibitory effect of calcium 
ions during protein C activation by thrombin, probably by 
masking E39 at the VR1 site. 
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